312 related articles for article (PubMed ID: 28445951)
1. PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma.
Fontugne J; Augustin J; Pujals A; Compagnon P; Rousseau B; Luciani A; Tournigand C; Cherqui D; Azoulay D; Pawlotsky JM; Calderaro J
Oncotarget; 2017 Apr; 8(15):24644-24651. PubMed ID: 28445951
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 expression in extrahepatic cholangiocarcinoma.
Walter D; Herrmann E; Schnitzbauer AA; Zeuzem S; Hansmann ML; Peveling-Oberhag J; Hartmann S
Histopathology; 2017 Sep; 71(3):383-392. PubMed ID: 28419539
[TBL] [Abstract][Full Text] [Related]
3. Programmed death ligand-1, tumor infiltrating lymphocytes and HLA expression in Chinese extrahepatic cholangiocarcinoma patients: Possible immunotherapy implications.
Yu F; Gong L; Mo Z; Wang W; Wu M; Yang J; Zhang Q; Li L; Yao J; Dong J
Biosci Trends; 2019 Mar; 13(1):58-69. PubMed ID: 30773525
[TBL] [Abstract][Full Text] [Related]
4. Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma - correlation with clinicopathological data and comparison of antibodies.
Kriegsmann M; Roessler S; Kriegsmann K; Renner M; Longuespée R; Albrecht T; Loeffler M; Singer S; Mehrabi A; Vogel MN; Pathil A; Köhler B; Springfeld C; Rupp C; Weiss KH; Goeppert B
BMC Cancer; 2019 Jan; 19(1):72. PubMed ID: 30646854
[TBL] [Abstract][Full Text] [Related]
5. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY
Front Immunol; 2021; 12():705378. PubMed ID: 34526987
[TBL] [Abstract][Full Text] [Related]
6. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH
J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276
[TBL] [Abstract][Full Text] [Related]
7. Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma.
Gani F; Nagarajan N; Kim Y; Zhu Q; Luan L; Bhaijjee F; Anders RA; Pawlik TM
Ann Surg Oncol; 2016 Aug; 23(8):2610-7. PubMed ID: 27012989
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-33 overexpression reflects less aggressive tumour features in large-duct type cholangiocarcinomas.
Sawada R; Ku Y; Akita M; Otani K; Fujikura K; Itoh T; Ajiki T; Fukumoto T; Kakeji Y; Zen Y
Histopathology; 2018 Aug; 73(2):259-272. PubMed ID: 29675965
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
[TBL] [Abstract][Full Text] [Related]
10. Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion.
Ye Y; Zhou L; Xie X; Jiang G; Xie H; Zheng S
J Surg Oncol; 2009 Nov; 100(6):500-4. PubMed ID: 19697355
[TBL] [Abstract][Full Text] [Related]
11. Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma.
Dong Z; Liao B; Shen W; Sui C; Yang J
Dig Dis Sci; 2020 Feb; 65(2):480-488. PubMed ID: 31410753
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.
Huang YH; Zhang CZ; Huang QS; Yeong J; Wang F; Yang X; He YF; Zhang XL; Zhang H; Chen SL; Zheng YL; Deng R; Lin CS; Yang MM; Li Y; Jiang C; Kin-Wah Lee T; Ma S; Zeng MS; Yun JP
J Hepatol; 2021 Apr; 74(4):838-849. PubMed ID: 33212090
[TBL] [Abstract][Full Text] [Related]
13. The PD-1/PD-L1 axis may be aberrantly activated in occupational cholangiocarcinoma.
Sato Y; Kinoshita M; Takemura S; Tanaka S; Hamano G; Nakamori S; Fujikawa M; Sugawara Y; Yamamoto T; Arimoto A; Yamamura M; Sasaki M; Harada K; Nakanuma Y; Kubo S
Pathol Int; 2017 Mar; 67(3):163-170. PubMed ID: 28139862
[TBL] [Abstract][Full Text] [Related]
14. M
Qiu X; Yang S; Wang S; Wu J; Zheng B; Wang K; Shen S; Jeong S; Li Z; Zhu Y; Wu T; Wu X; Wu R; Liu W; Wang HY; Chen L
Cancer Res; 2021 Sep; 81(18):4778-4793. PubMed ID: 34301762
[TBL] [Abstract][Full Text] [Related]
15. ASO Author Reflections: Clinical Significance of PD-L1 Expression in Both Cancer and Stroma Cells in Cholangiocarcinoma Patients.
Kitano Y; Baba H
Ann Surg Oncol; 2020 Feb; 27(2):608-609. PubMed ID: 31691113
[No Abstract] [Full Text] [Related]
16. Cancer-associated fibroblast senescence and its relation with tumour-infiltrating lymphocytes and PD-L1 expressions in intrahepatic cholangiocarcinoma.
Lan C; Kitano Y; Yamashita YI; Yamao T; Kajiyama K; Yoshizumi T; Fukuzawa K; Sugimachi K; Ikeda Y; Takamori H; Miyanari N; Hirota M; Baba H
Br J Cancer; 2022 Feb; 126(2):219-227. PubMed ID: 34616011
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma.
Sabbatino F; Villani V; Yearley JH; Deshpande V; Cai L; Konstantinidis IT; Moon C; Nota S; Wang Y; Al-Sukaini A; Zhu AX; Goyal L; Ting DT; Bardeesy N; Hong TS; Fernandez-del Castillo C; Tanabe KK; Lillemoe KD; Ferrone S; Ferrone CR
Clin Cancer Res; 2016 Jan; 22(2):470-8. PubMed ID: 26373575
[TBL] [Abstract][Full Text] [Related]
18. Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report.
Mou H; Yu L; Liao Q; Hou X; Wu Y; Cui Q; Yan N; Ma R; Wang L; Yao M; Wang K
BMC Cancer; 2018 Nov; 18(1):1105. PubMed ID: 30419854
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic implications of CD8
Zou MX; Guo KM; Lv GH; Huang W; Li J; Wang XB; Jiang Y; She XL
Cancer Immunol Immunother; 2018 Feb; 67(2):209-224. PubMed ID: 29051990
[TBL] [Abstract][Full Text] [Related]
20. Clinical Significance of PD-L1 Expression in Both Cancer and Stroma Cells of Cholangiocarcinoma Patients.
Kitano Y; Yamashita YI; Nakao Y; Itoyama R; Yusa T; Umezaki N; Tsukamoto M; Yamao T; Miyata T; Nakagawa S; Okabe H; Imai K; Chikamoto A; Ishiko T; Baba H
Ann Surg Oncol; 2020 Feb; 27(2):599-607. PubMed ID: 31407173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
